Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies (NYSE: A) has declared a quarterly dividend of 24.8 cents per share of common stock. The dividend will be paid on October 22, 2025, to shareholders of record as of September 30, 2025. Future dividend payments remain subject to board approval.
Agilent Technologies (NYSE: A) announced that President and CEO Padraig McDonnell will participate in a fireside chat at the Bank of America Global Healthcare Conference in London. The presentation is scheduled for September 25, 2025, from 9:50-10:30 AM BST. Investors can access both the live audio webcast and replay through Agilent's Investor Relations website.
Agilent Technologies (NYSE: A) has achieved the highest level of My Green Lab Certification—Green level—at its Refurbishment Centers in Delaware, USA, and Singapore. The centers scored 90% and 87% respectively in rigorous sustainability assessments across 12 critical categories.
The certification highlights Agilent's Certified Pre-Owned (CPO) program, which restores used instruments to factory-grade condition, supporting a circular lab economy through trade-in and buy-back options. Approximately 50% of refurbishment team members have become My Green Lab Ambassadors, demonstrating the company's commitment to sustainability.
Agilent Technologies (NYSE: A) announced its participation as a premium sponsor at the European Congress of Pathology (ECP) 2025 in Vienna, Austria, from September 6-10, 2025. The company will showcase the European launch of its expanded Dako Omnis Family of instruments, including the Dako Omnis 110, 165, and 165 Duo models.
The event will feature live demonstrations, expert sessions, and educational symposia focusing on diagnostic excellence and workflow optimization. Visitors can explore Agilent's Digital Pathology solutions and participate in PD-L1 CPS scoring sessions at booth #18.
Agilent Technologies (NYSE: A) has achieved a significant regulatory milestone as its MMR IHC Panel pharmDx (Dako Omnis) received European IVDR certification as a class C companion diagnostic test for colorectal cancer. The panel is specifically designed to identify mismatch repair (MMR) deficient CRC patients who may be eligible for treatment with OPDIVO® in combination with YERVOY®.
The diagnostic panel is uniquely positioned as the only companion diagnostic IHC panel IVDR approved for this specific treatment combination in colorectal cancer patients. The test works by detecting the loss of function in four key MMR proteins (MLH1, PMS2, MSH2, and MSH6) in tissue samples, helping identify patients who may respond better to immunotherapy.
Agilent Technologies (NYSE: A) reported strong Q3 2025 financial results with revenue of $1.74 billion, representing 10.1% reported growth and 6.1% core growth year-over-year. The company achieved GAAP EPS of $1.18 (up 22%) and non-GAAP EPS of $1.37 (up 4%).
All three business segments showed growth: Life Sciences and Diagnostics Markets Group revenue increased 14% to $670 million, Agilent CrossLab Group grew 8% to $744 million, and Applied Markets Group rose 7% to $324 million.
Agilent raised its full-year 2025 outlook, projecting revenue between $6.91-6.93 billion (6.2-6.5% growth) and non-GAAP EPS of $5.56-5.59. Q4 2025 revenue is expected at $1.822-1.842 billion with non-GAAP EPS of $1.57-1.60.
Agilent Technologies (NYSE: A) announced that President and CEO Padraig McDonnell will participate in a fireside chat at the Wells Fargo Healthcare Conference. The presentation is scheduled for September 3, 2025, from 11:00 to 11:35 AM ET in Everett, Massachusetts. Investors can access both the live audio webcast and replay through Agilent's Investor Relations website.
Agilent Technologies (NYSE: A) has received FDA approval for its MMR IHC Panel pharmDx (Dako Omnis) as a companion diagnostic test for colorectal cancer. The test identifies mismatch repair deficient (dMMR) colorectal cancer patients eligible for treatment with Bristol Myers Squibb's Opdivo alone or in combination with Yervoy.
The panel is the only FDA-approved companion diagnostic IHC panel for this specific purpose and is exclusively designed for use with Agilent's Dako Omnis automated staining solution. The test detects loss of function in four key MMR proteins (MLH1, PMS2, MSH2, and MSH6) in colorectal cancer tissue, helping identify patients who may respond better to immunotherapy.
Agilent Technologies (NYSE:A) and Georgia Tech have announced the establishment of an Agilent Center of Excellence (CoE) for Environmental Health and Engineering. The center will be led by renowned environmental scientist Professor Shane Snyder from Georgia Tech's School of Civil and Environmental Engineering.
The CoE will focus on advancing research in environmental sustainability, water recycling, and biologics. Key research areas include developing novel water recycling technologies, waste material upcycling, and cell-based analysis of environmental mixtures. This marks Agilent's third CoE in the U.S. and will be uniquely positioned to evaluate environmental contaminants and toxicity.
Agilent Technologies (NYSE: A) has launched three new models in its Dako Omnis instrument family to address diverse pathology laboratory needs. The new lineup includes the Dako Omnis 110 for low-medium volume labs (110 IHC slides/day), Dako Omnis 165 for medium-high volume labs (165 IHC slides/day), and Dako Omnis 165 Duo for simultaneous IHC and ISH processing.
The new instruments feature continuous case-based processing, shared reagents, and an integrated direct connection for de-ionized water and non-hazardous waste to improve workflow efficiency. The products will be initially available in the U.S., Europe, and Australia, with debuts planned at the European Congress of Pathology and National Society for Histotechnology events.